Duration 5min, Q&A 3min
Imiquimod Cream in the Treatment of Periocular Nodular Basal Cell Carcinoma
The recurrence rate of nodular basal cell carcinoma (BCC) following treatment with imiquimod has not yet been established. Although no recurrence has been reported in studies on nodular BCC in the periocular region, it should be pointed out that previous studies did not include histological follow-up. The aim of this analysis is evaluate the efficacy of topical immunotherapy with 5% imiquimod cream in the treatment of periocular nodular BCC.
Main Outcome Measures: clinical and histological cure rate.
This is a prospective, noncomparative, consecutive, interventional clinical study carried at university hospital. Pacients were punch biopsy confirmed periocular nodular BCC cases
Patients were treated with 5% imiquimod cream. The medication was applied once a day, five days a week for 8-16 weeks. We performed standard lesion photographic documentation along the study. Images were analyzed using the software Image J. Three months after treatment completion, an image-guided biopsy of the region was performed. Patients have been followed at 6-month intervals since treatment completion, with annual control biopsies.
Results and Conclusion
Throughout the study period, 24 patients met inclusion criteria, 19 of which remained until the end of treatment. The histological cure rate was 89.5% at 3 months and 84.2% at 39.5 months. The 3-year histological cure rate was 81.8% (9/11) for lesions >10 mm, and 100% (8/8) for lesions <10 mm. 5% imiquimod cream was shown to be an efficacious alternative treatment for nodular periocular BCC, especially for lesions <10 mm. It also had a significant neoadjuvant effect on lesions >10 mm which were not completely cured.
[ Keyword ]
Basal cell carcinoma / topical administration / immunotherapy / antineoplastic drugs / periocular neoplasms/therapy
[ Conflict of Interest ]